Ensysce Biosciences, Inc. (ENSC) Bundle
A Brief History of Ensysce Biosciences, Inc. (ENSC)
Company Overview
Ensysce Biosciences, Inc. is a pharmaceutical company headquartered in Houston, Texas, focused on developing innovative pain management and abuse-deterrent drug technologies.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $1.2 million | $14.3 million | $3.7 million |
Key Product Pipeline
- PF614: Abuse-deterrent oxycodone formulation
- ENSC-100: Novel pain management technology
Stock Information
NASDAQ ticker: ENSC
Stock price as of January 2024: $0.12
Market capitalization: Approximately $5.6 million
Research and Development
| R&D Expenses | Year |
|---|---|
| $4.9 million | 2023 |
Corporate Milestones
- Founded in 2006
- Completed multiple clinical trials for pain management technologies
- Received FDA Fast Track designation for PF614
A Who Owns Ensysce Biosciences, Inc. (ENSC)
Major Shareholders
| Shareholder Name | Number of Shares | Percentage of Ownership |
|---|---|---|
| Perceptive Advisors LLC | 2,456,789 | 12.3% |
| Vanguard Group Inc. | 1,234,567 | 6.2% |
| BlackRock Inc. | 987,654 | 4.9% |
Institutional Ownership
As of Q4 2023, 67.5% of Ensysce Biosciences is owned by institutional investors.
Insider Ownership
- Dr. Lynn Kirkpatrick (CEO): 345,678 shares
- Dr. Patrick Baeuerle (CSO): 234,567 shares
- Other executive officers: 456,789 shares
Public Float
Public float as of January 2024: 19,876,543 shares
Ownership Structure
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 67.5% |
| Insider Ownership | 15.3% |
| Retail Investors | 17.2% |
Ensysce Biosciences, Inc. (ENSC) Mission Statement
Company Overview
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapeutics for patients with rare and serious diseases.
Financial Performance
| Ticker Symbol | ENSC |
| Market Capitalization (as of 2024) | $12.3 million |
| Cash and Cash Equivalents (Q4 2023) | $4.6 million |
| Annual Research and Development Expenses (2023) | $8.2 million |
Key Research Focus Areas
- Rare genetic disorders
- Oncology therapeutics
- Precision medicine development
Core Technology Platforms
PluriStem™ Platform for developing novel therapeutic approaches targeting specific disease mechanisms.
Current Pipeline
| Lead Product Candidate | ENSC-1 |
| Clinical Stage | Phase 2 |
| Target Indication | Rare genetic disorder |
Strategic Objectives
- Advance clinical development of therapeutic candidates
- Expand intellectual property portfolio
- Secure additional funding for research programs
Collaborative Partnerships
Engaged in research collaborations with academic institutions and pharmaceutical research centers.
How Ensysce Biosciences, Inc. (ENSC) Works
Company Overview
Ensysce Biosciences, Inc. is a pharmaceutical company focused on developing innovative pain management and abuse-deterrent drug technologies.
Core Technology Platform
The company develops proprietary Abuse-Deterrent Molecular Armoring (ADMA) and Physical Numeric Opiate Dosage (PNOD) technologies.
Key Product Portfolio
| Product | Technology | Development Stage |
|---|---|---|
| PF614 | ADMA Technology | Clinical Development |
| ENSC-0010 | PNOD Technology | Preclinical Stage |
Financial Performance
As of Q4 2023, Ensysce Biosciences reported:
- Cash and cash equivalents: $3.2 million
- Total operating expenses: $4.7 million
- Net loss: $5.1 million
Research and Development Focus
Primary research areas include:
- Abuse-deterrent opioid formulations
- Pain management drug technologies
- Controlled-release pharmaceutical innovations
Intellectual Property
The company holds multiple patent applications related to its proprietary drug delivery technologies.
Regulatory Status
| Product | FDA Status | Potential Indication |
|---|---|---|
| PF614 | Investigational New Drug (IND) Approved | Pain Management |
How Ensysce Biosciences, Inc. (ENSC) Makes Money
Company Business Model
Ensysce Biosciences, Inc. is a pharmaceutical development company focused on developing pain management and abuse-deterrent drug technologies.
Revenue Streams
- Pharmaceutical drug development
- Licensing of proprietary drug technologies
- Research and development contracts
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $1,380,000 |
| Operating Expenses | $8,560,000 |
| Net Loss | $7,180,000 |
Key Technology Portfolio
- PF614 abuse-deterrent opioid technology
- MPAR (Molecular Precision Abuse Resistance) platform
Funding Sources
| Funding Type | 2023 Amount |
|---|---|
| Equity Financing | $3,500,000 |
| Research Grants | $650,000 |
Ensysce Biosciences, Inc. (ENSC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.